RxDoctor Payments Data

Steven Taylor, MD

Family Medicine · O Fallon, ILNPI 1073831533

Payments from drug & device makers

$9,352in general payments, 2019–2025

Across 544 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Astrazeneca UK Limited$1K
  • Novo Nordisk$775
  • Lilly USA, LLC$685
  • Pfizer$661
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$1,00311%
  • Food & beverage$7,78083%
  • Education$80%
  • Other$5606%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,352 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$129,131
Medicare patients
281
Services billed
1,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$114,164
MounjaroTirzepatide84$95,986
FarxigaDapagliflozin Propanediol85$92,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$67,280
OzempicSemaglutide33$63,499
EliquisApixaban51$52,911
TrulicityDulaglutide30$45,934
Synjardy XrEmpagliflozin/Metformin Hcl28$30,222
XareltoRivaroxaban22$22,450
VraylarCariprazine Hcl13$20,754
Tresiba Flextouch U-200Insulin Degludec19$19,356
MyrbetriqMirabegron32$17,544
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$16,520
Breo ElliptaFluticasone/Vilanterol19$15,932
LinzessLinaclotide11$11,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$282$144,386121 claims
Lilly USA, LLCMounjaro, Trulicity$685$141,919114 claims
AstraZenecaFarxiga$1,302$92,94585 claims
GSKTrelegy Ellipta, Breo Ellipta$183$83,21286 claims
Novo NordiskOzempic$775$63,49933 claims
PfizerEliquis, Premarin$661$56,35465 claims
AbbVieVraylar, Linzess$1,326$32,30324 claims
Johnson & JohnsonXarelto$270$22,45022 claims
Astellas Pharma US IncMyrbetriq$64$17,54432 claims
MerckJanumet Xr$94$6,88012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in O Fallon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →